{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:08Z","timestamp":1792592408037,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.advms.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T04:23:56Z","timestamp":1725942236000},"page":"407-415","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8333-7570","authenticated-orcid":false,"given":"Grzegorz","family":"Procyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jaworski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"G\u0105secka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-8146","authenticated-orcid":false,"given":"Josip A.","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2024.09.001_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A\u00a0multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"M\u00e9ndez-S\u00e1nchez","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.advms.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.advms.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib5","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.advms.2024.09.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100765","article-title":"NAFLD VS MAFLD. The evidence-based debate has come. Time to change?","volume":"27","author":"Garc\u00eda-Compe\u00e1n","year":"2022","journal-title":"Ann Hepatol"},{"issue":"9","key":"10.1016\/j.advms.2024.09.001_bib7","first-page":"e733","article-title":"Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS) - april 2022 - AWMF registration No.: 021-025","volume":"60","year":"2022","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.advms.2024.09.001_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","article-title":"Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD)","volume":"13","author":"Duseja","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MOG.0000000000000823","article-title":"Metabolic dysfunction-associated fatty liver disease: a year in review","volume":"38","author":"Alharthi","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.advms.2024.09.001_bib11","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","article-title":"Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals","volume":"107","author":"Chan","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.advms.2024.09.001_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","article-title":"Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight","volume":"19","author":"Eslam","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.dld.2010.01.016","article-title":"From the metabolic syndrome to NAFLD or vice versa?","volume":"42","author":"Vanni","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.advms.2024.09.001_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clnesp.2023.10.001","article-title":"Investigation about the correlation between the severity of metabolic-associated fatty liver disease and adherence to the Mediterranean diet","volume":"58","author":"Mokhtare","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.advms.2024.09.001_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1392280","article-title":"Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related\/associated steatotic liver disease: a study on Japanese participants undergoing health checkups","volume":"15","author":"Fukuda","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.advms.2024.09.001_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15947","article-title":"Exercise improves surrogate measures of liver histological response in metabolic dysfunction-associated steatotic liver disease","author":"Cuthbertson","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.advms.2024.09.001_bib17","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.advms.2024.09.001_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cts.12839","article-title":"Evolving role for pharmacotherapy in NAFLD\/NASH","volume":"14","author":"Attia","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.advms.2024.09.001_bib20","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.advms.2024.09.001_bib21","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.advms.2024.09.001_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium\u2013glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.advms.2024.09.001_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","article-title":"Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis","volume":"100","author":"Gronda","year":"2022","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.advms.2024.09.001_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.advms.2024.09.001_bib25","article-title":"The effect of empagliflozin on liver fat in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease","volume":"13","author":"Pokharel","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.advms.2024.09.001_bib26","first-page":"280","article-title":"Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus","volume":"67","author":"Shinozaki","year":"2020","journal-title":"J\u00a0Med Invest"},{"key":"10.1016\/j.advms.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.advms.2024.09.001_bib28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.advms.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.advms.2024.09.001_bib30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.advms.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep4.2005","article-title":"Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: a 5-year follow-up study","volume":"6","author":"Akuta","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.advms.2024.09.001_bib32","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.advms.2024.09.001_bib33","first-page":"62","article-title":"Effects of canagliflozin on abnormal liver function tests in patients of type 2 diabetes with non-alcoholic fatty liver disease","volume":"66","author":"Gautam","year":"2018","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.advms.2024.09.001_bib34","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.advms.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.advms.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2024.09.001_bib37","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/jdi.13457","article-title":"Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone","volume":"12","author":"Cho","year":"2021","journal-title":"J\u00a0Diabetes Investig"},{"key":"10.1016\/j.advms.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J\u00a0Diabetes Investig."},{"key":"10.1016\/j.advms.2024.09.001_bib39","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/dom.14004","article-title":"Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes","volume":"22","author":"Johansson","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.advms.2024.09.001_bib40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/dom.13907","article-title":"Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes","volume":"22","author":"Gastaldelli","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.advms.2024.09.001_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.advms.2024.09.001_bib42","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.advms.2024.09.001_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.advms.2024.09.001_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.EJ18-0217","article-title":"Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results)","volume":"66","author":"Tabuchi","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.advms.2024.09.001_bib45","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.advms.2024.09.001_bib46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","article-title":"Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects","volume":"64","author":"Takase","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.advms.2024.09.001_bib47","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40261-016-0383-1","volume":"36","author":"Ohki","year":"2016","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.advms.2024.09.001_bib48","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.advms.2024.09.001_bib49","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.advms.2024.09.001_bib50","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.advms.2024.09.001_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.945626","article-title":"Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: a retrospective case-control study","volume":"13","author":"Ba\u00f1ares","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.advms.2024.09.001_bib52","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.3748\/wjg.v28.i26.3243","article-title":"Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis\/fibrosis\/inflammation and redox balance in non-alcoholic fatty liver disease","volume":"28","author":"Bellanti","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.advms.2024.09.001_bib53","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","article-title":"Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus","volume":"6","author":"Arai","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.advms.2024.09.001_bib54","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2337\/dc21-1953","article-title":"Glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors and risk of nonalcoholic fatty liver disease among patients with type 2 diabetes","volume":"45","author":"Pradhan","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.advms.2024.09.001_bib55","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/dom.14616","article-title":"Elevated liver enzymes and comorbidities in type 2 diabetes: a multicentre analysis of 51 645 patients from the Diabetes Prospective Follow-up (DPV) database","volume":"24","author":"Meyh\u00f6fer","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.advms.2024.09.001_bib56","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1080\/03007995.2021.1965563","article-title":"Effect of newer antihyperglycemic drugs on liver steatosis indices in patients with diabetes and obesity","volume":"37","author":"Carretero G\u00f3mez","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.advms.2024.09.001_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.613389","article-title":"Sodium-glucose cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Euh","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.advms.2024.09.001_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002243","article-title":"Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes","volume":"9","author":"Loosen","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.advms.2024.09.001_bib59","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.2169\/internalmedicine.2566-18","article-title":"The long-term efficacy of sodium glucose Co-transporter 2 inhibitor in patients with non-alcoholic fatty liver disease","volume":"58","author":"Yamashima","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.advms.2024.09.001_bib60","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-019-00785-6","article-title":"Effect of sodium glucose Co-transporter 2 inhibitors on liver fat mass and body composition in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"39","author":"Arase","year":"2019","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.advms.2024.09.001_bib61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.diabet.2018.08.001","article-title":"SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes","volume":"44","author":"Bajaj","year":"2018","journal-title":"Diabetes Metab"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611262400049X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S189611262400049X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:01:16Z","timestamp":1730739676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S189611262400049X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S189611262400049X"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2024.09.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease - A new indication for sodium-glucose Co-transporter-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Medical University of Bialystok.","name":"copyright","label":"Copyright"}]}}